March 2022

March 30, 2022September 25, 2024

AstraZeneca and Huma Therapeutics | Signalling a New Type of Relationship

This week’s announcement of the sale of AstraZeneca’s chronic disease management platform, AMAZE™, to Huma Therapeutics in return for a stake in the company and collaborative partnership has generated a mix of responses.

I see this neither as a spin off from a biopharma losing interest in digital healthcare, nor an attempt to catch up with peers that have already launched digital therapeutics products – as has been suggested by others.

March 10, 2022March 30, 2022

Amazon and Babylon Mount Their US Telehealth Bid | So What? | Part 2 Babylon Unpacked

To Make an Imprint, Babylon Has to Keep Moving Deeper into the Clinical Stack

Babylon set the primary care market alight when it launched back in 2013 as the hero Healthcare needed, intent on disrupting the inequitable primary care model.

9 years on, and rarely out of the headlines, it’s certainly progressed, but the bold ambition it laid out hasn’t been fully realised. Along the way, it’s accumulated as many critics and sceptics as it has fans.

error: Content is protected !!